If you had a heart condition and your surgeon wanted to implant a defibrillator in your body that was based on one with a dangerous defect, wouldn’t you want to know that the safety flaw had been fixed?
Of course you would.
Under current law, however, the Food and Drug Administration doesn’t have the power to require device makers in most cases to prove they’ve fixed safety flaws when they want to market a new device based on one that has been recalled by manufacturers.
Right now Congress is updating the law that governs medical devices in the United States, so there’s an opportunity to close this absurd loophole in our current oversight system.
If you’re like most people, you probably assume that all medical devices are required to undergo clinical testing to prove they are safe and effective before the FDA allows them on the market. Far too often, that’s not the case.
Surprisingly, more than 90 percent of medical devices do not require clinical testing before the FDA clears them for sale. While such testing may not be necessary for simple devices such as crutches or walkers, an alarming number of complex devices are implanted in patients’ bodies without this kind of review.
Instead, the FDA allows most devices to be sold based on whether they are “substantially equivalent” to devices that are already on the market. By law, the FDA can consider only whether the new device is similar to one already being sold and no evidence of clinical testing is required — even when the device it is based on has been recalled by manufacturers because of safety problems.
Believe it or not, if the manufacturer can prove the new device is substantially equivalent to the recalled device, then the FDA must clear it for sale even if the agency is aware that the device repeats the same design flaws.
The consequences can be disastrous for patients. Perhaps the most well-known example of this dangerous problem involves vaginal mesh implants used to treat urinary incontinence and weak pelvic organs in women. Surgeons implant the mesh in patients to strengthen tissue weakened by childbirth or age and to keep the women’s internal organs in place.
The first vaginal mesh implant was introduced by Boston Scientific, which received clearance from the FDA to market its ProtoGen bladder sling in 1997. The mesh sling was based on another device used for cardiovascular operations. But just two years later, the bladder sling was recalled after hundreds of women with the device reported experiencing serious complications, including debilitating pain and life-threatening infections.
Despite the recall, several vaginal mesh products have been cleared by the FDA since that time based on their substantial equivalence to the dangerous device that was recalled by its manufacturer. Not surprisingly, the problems women have experienced with vaginal mesh implants have not been unique to the recalled device and the FDA has received thousands of complaints from injured patients.
Leaders from military and veterans service organizations joined Sens. Roger Wicker, R-Miss., Kelly Ayotte , R-N.H., and Lindsey Graham, R-S.C., at a press conference to urge the Senate to replace a provision in the budget proposal that cuts retirement benefits for veterans. Wicker, Ayotee, and Graham earlier called for a bipartisan solution to replace the $6.3 billion in cuts to military retiree benefits.
Each year since 1990, CQ Roll Call has reviewed the financial disclosures of all 541 senators, representatives and delegates to determine the 50 richest members of Congress. This year's report, derived from forms covering the calendar year 2012, shows it took a net worth of $6.67 million to crack the exclusive club.